Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.

被引：62
|
作者：
Gadgeel, Shirish M.
Stevenson, James
Langer, Corey J.
Gandhi, Leena
Borghaei, Hossein
Patnaik, Amita
Villaruz, Liza Cosca
Gubens, Matthew A.
Hauke, Ralph J.
Yang, James Chih-Hsin
Sequist, Lecia V.
Bachman, Robert D.
Ge, Joy Yang
Raftopoulos, Harry
Papadimitrakopoulou, Vassiliki
机构：
[1] Karmanos Canc Inst, Detroit, MI USA
[2] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[6] South Texas Accelerated Res Theraput, San Antonio, TX USA
[7] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
[9] Nebraska Canc Specialists, Omaha, NE USA
[10] Natl Taiwan Univ Hosp, Taipei, Taiwan
[11] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[12] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[13] Harvard Med Sch, Boston, MA 02115 USA
[14] Merck & Co Inc, Kenilworth, NJ USA
[15] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.9016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9016
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).
    Ozguroglu, Mustafa
    Alva, Ajjai Shivaram
    Csoszi, Tibor
    Matsubara, Nobuaki
    Geczi, Lajos
    Cheng, Susanna Y.
    Fradet, Yves
    Oudard, Stephane
    Vulsteke, Christof
    Morales-Barrera, Rafael
    Flechon, Aude
    Gunduz, Seyda
    Loriot, Yohann
    Rodriguez-Vida, Alejo
    Mamtani, Ronac
    Yu, Evan Y.
    Nam, Kijoeng
    Imai, Kentaro
    Moreno, Blanca Homet
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [32] Pembrolizumab (pembro) 1 chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407
    Paz-Ares, L.
    Vicente, D.
    Tafreshi, A.
    Robinson, A.
    Soto Parra, H.
    Mazieres, J.
    Hermes, B.
    Cicin, I.
    Medgyasszay, B.
    Beatrix, B.
    Rodriguez Cid, J.
    Okamoto, I.
    Lee, S.
    Ramlau, R.
    Vladimirov, V.
    Cheng, Y.
    Deng, X.
    Bas, T.
    Piperdi, B.
    Halmos, B.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] Pembrolizumab plus Chemotherapy as First-Line Treatment in advanced Oesophageal Cancer (KEYNOTE-590)
    Hartmann, Milan
    Zander, Thomas
    Alakus, Hakan
    ONKOLOGE, 2022, 28 (05): : 436 - 437
  • [34] Advanced Esophageal Cancer: Pembrolizumab plus Chemotherapy as First-line Therapy
    Franke, Katharina
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2021, 59 (12): : 1255 - +
  • [35] Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
    Kato, K.
    Sun, J-M.
    Shah, M. A.
    Enzinger, P. C.
    Adenis, A.
    Doi, T.
    Kojima, T.
    Metges, J-P.
    Li, Z.
    Kim, S-B.
    Cho, B. C. Chul
    Mansoor, W.
    Li, S-H.
    Sunpaweravong, P.
    Maqueda, M. A.
    Goekkurt, E.
    Liu, Q.
    Shah, S.
    Bhagia, P.
    Shen, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S1192 - S1193
  • [36] KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
    Reck, M.
    Rodr-Guez-Abreu, D.
    Robinson, A. G.
    Hui, R.
    Csoszi, T.
    Fulop, A.
    Gottfried, M.
    Peled, N.
    Tafreshi, A.
    Cuffe, S.
    O'Brien, M.
    Rao, S.
    Hotta, K.
    Leiby, M.
    Lubiniecki, G. M.
    Shentu, Y.
    Rangwala, R.
    Brahmer, J. R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
    Reck, M.
    Rodriguez-Abreu, D.
    Robinson, A.
    Hui, R.
    Csoszi, T.
    Fulop, A.
    Gottfried, M.
    Peled, N.
    Tafreshi, A.
    Cuffe, S.
    O'Brien, M. E.
    Rao, S.
    Hotta, K.
    Leiby, M.
    Lubiniecki, G.
    Shentu, Y.
    Rangwala, R.
    Brahmer, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
    Shiu, Kai-Keen
    Rivera, Fernando
    Medley, Louise C.
    Aghmesheh, Morteza
    Dunne, Richard Francis
    Roy, Rajarshi
    Wyrwicz, Lucjan S.
    Larson, Timothy
    Metges, Jean-Philippe
    Mansoor, Wasat
    Goekkurt, Eray
    Moreira Antunes, Luiz Carlos
    Castro Oliden, Victor
    Jensen, Erin
    Shah, Sukrut
    Bordia, Sonal
    Bhagia, Pooja
    Lowery, Maeve Aine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 345 - 345
  • [39] KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab plus Chemotherapy for Metastatic Nonsquamous NSCLC
    Gadgeel, S.
    Garassino, M. C.
    Esteban, E.
    Speranza, G.
    Felip, E.
    Hochmair, M. J.
    Powell, S.
    Cheng, S. Y. -S.
    Bischoff, H. G.
    Peled, N.
    Hui, R.
    Reck, M.
    Kurata, T.
    Garon, E. B.
    Boyer, M.
    Yang, J.
    Pietanza, M. C.
    Rodriguez-Abreu, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1153 - S1153
  • [40] Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
    Rha, S. Y.
    Wyrwicz, L. S.
    Weber, P. E. Y.
    Bai, Y.
    Ryu, M. H.
    Lee, J.
    Rivera, F.
    Alves, G. V.
    Garrido, M.
    Shiu, K. -k.
    Fernandez, M. Gonzalez
    Li, J.
    Lowery, M.
    Cil, T.
    Cruz, F. J. S. M.
    Qin, S.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Oh, D-y.
    ANNALS OF ONCOLOGY, 2023, 34 (03) : 319 - 320
12345